目的 研究米格列醇聯(lián)合格列吡嗪對2型糖尿病的療效。方法 選擇2016年1月—2019年1月榮縣人民醫(yī)院的98例2型糖尿病患者作為研究對象，用抽簽法隨機將患者分為對照組和觀察組，每組各49例。對照組口服格列吡嗪片，起始的劑量為5 mg/d，最大的給藥劑量為5～10 mg/次，2次/d。觀察組在對照組的基礎(chǔ)上服用米格列醇片，50 mg/次，3次/d。兩組均治療12周。觀察兩組患者的臨床療效，同時比較兩組患者的血糖水平和不良反應(yīng)發(fā)生情況。結(jié)果 治療后，觀察組治療的總有效率為91.84%，明顯高于對照組的73.47%（P<0.05）。兩組治療后的空腹血糖（FBG）、糖化血紅蛋白（HbA1c）和餐后2 h血糖（2 h PG）均明顯降低（P<0.05），且治療后觀察組血糖指標(biāo)水平明顯更低（P<0.05）。兩組治療期間不良反應(yīng)的發(fā)生情況對比無統(tǒng)計學(xué)差異。結(jié)論 米格列醇聯(lián)合格列吡嗪對2型糖尿病的療效確切，能有效降低患者的血糖水平，安全有效，值得臨床上應(yīng)用。

Objective To study the effect of miglitol combined with glipizide on type 2 diabetes mellitus. Methods A total of 98 patients with type 2 diabetes in Rongxian People's Hospital from January 2016 to January 2019 were selected as the research objects, and randomly divided into control group and observation group by lottery, with 49 patients in each group. Patients in the control group were po administered with Glipizide Tablets, the initial dose was 5 mg/d, and the maximum dose was 5-10 mg/d, twice daily. Patients in the observation group were po administered with Miglitol Tablets on the basis of the control group, 50 mg/time, three times daily. Both groups were treated for 12 weeks. After treatment, the clinical efficacy in two groups were observed, and the blood glucose level and adverse reactions were compared. Results After treatment, the total effective rate in the observation group was 91.84%, which was significantly higher than 73.47% in the control group (P<0.05). After treatment, the levels of FBG, HbA1c, and 2 h PG in two groups were significantly decreased (P<0.05), and the blood glucose index level in the observation group was significantly lower than those in the control group (P<0.05). There was no statistical difference in the occurrence of adverse reactions between the two groups during treatment. Conclusion Miglitol combined with glipizide has a definite therapeutic effect on type 2 diabetes, can effectively reduce the blood glucose level of patients, safe and effective, and is worthy of clinical application.

R977